

CORRECTION

Correction: ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance *in vitro*, in both cell lines and primary patient mononuclear cells

The *PLOS ONE* Staff

[S1 Table](#) is omitted from the list of Supporting Information. It can be viewed below.

[S1 File](#) is also omitted from the list of Supporting Information. It can be viewed below.

The publisher apologizes for the errors.

Supporting information

S1 Table. Summary of inhibitors used in this study and the corresponding cellular transporters upon which they act.


(DOCX)

S1 File. Supplementary methods.

(DOCX)

Reference

1. Eadie LN, Dang P, Goynes JM, Hughes TP, White DL (2018) ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance *in vitro*, in both cell lines and primary patient mononuclear cells. *PLoS ONE* 13(1): e0192180. <https://doi.org/10.1371/journal.pone.0192180> PMID: 29385210



OPEN ACCESS

Citation: The *PLOS ONE* Staff (2018) Correction: ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance *in vitro*, in both cell lines and primary patient mononuclear cells. *PLoS ONE* 13(8): e0203583. <https://doi.org/10.1371/journal.pone.0203583>

Published: August 31, 2018

Copyright: © 2018 The PLOS ONE Staff. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.